Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Conditions
Keywords
neurodegeneration, neurodegenerative disease, cbs, cbd, corticobasal syndrome, corticobasal degeneration
Brief summary
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
Detailed description
Corticobasal syndrome (CBS) is a neurodegenerative disorder characterized by cognitive and behavioral change, as well as asymmetric parkinsonism, dystonia, myoclonus, and limb apraxia. Emerging evidence suggests neuroinflammation plays a key role in the pathogenesis of neurodegenerative disease, including the 4R tauopathies and AD, and neuroinflammation has been linked mechanistically to damage of the white matter. The primary goal of this study is to investigate inflammation and white matter damage using imaging and blood samples. The investigator's will use the PET ligand 11C-ER176 to assess patterns of neuroinflammation in the brain and Neurite Orientation Dispersion and Density Imaging (NODDI) to measure white matter microstructure, including axonal density and alignment. The investigator's will also investigate blood plasma metrics, including neurofilament light chain and plasma glial fibrillary acidic protein (GFAP) that measure neuroaxonal injury and astrogliosis, and inflammation and tau metrics. The investigator's will employ beta-amyloid (A) and tau (T) PET to subdivide the CBS patients into those with biomarker AD (A+T+, CBS-AD) and those without biomarker AD (CBS-4R). The investigator's will also compare these groups to disease controls with typical amnestic biomarker AD (Amn-AD) and healthy controls (HC) that have previously been recruited for other grants (existing data collected under approved IRBs).
Interventions
DIAGNOSTIC_TESTC-11 ER176 Radiotracer
PET scan looking for inflammation
DIAGNOSTIC_TESTC-11 PiB
PET scan looking for amyloid protein
DIAGNOSTIC_TESTAV1451 Tau
Pet scan looking for Tau protein
Sponsors
National Institute on Aging (NIA)
Jennifer Whitwell
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older * Meet possible or probable CBS criteria
Exclusion criteria
* Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The investigators will use C-11 ER176 PET imaging to evaluate neuroinflammation and white matter integrity in CBS | approximately 4-5 years into study visits | Measure whether regional patterns of ER176-PET uptake and white matter microstructure abnormalities using NODDI differ between CBS-4R, CBS-AD, Amn-AD, and HC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the investigators will use blood samples to assess inflammatory and tau blood plasma metrics in CBS. | approximately 4-5 years into study visits | Measure whether plasma metrics differ between CBS-4R, CBS-AD, Amn-AD, and HC. |
Other
| Measure | Time frame |
|---|---|
| The investigators will use MR imaging to compare regional markers of inflammation, white matter integrity and tau burden in autopsy tissue from patients with CBS from two different 4R tauopathies and CBS-AD. | Approximately 8-10 years after study completion |
Countries
United States
Contacts
Primary ContactMegan J Meyer, M.B.A.
Backup ContactSarah M Boland, CCRP
Outcome results
None listed